Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16950734 | 0.93 | CNR1 (0.34) | CNR1CNR2CA2LPLLIPG | |
| SCHEMBL16960867 | 0.91 | HPGD (0.42) | CA2GPR84CYP3A4PTGS2 | |
| SCHEMBL16952596 | 0.89 | CNR1 (0.36) | CNR1CNR2CA2LPLLIPG | |
| SCHEMBL5210187 | 0.85 | GAA (0.34) | CNR1CNR2CA2LPLLIPG | |
| SCHEMBL8383495 | 0.85 | FFAR4 (0.35) | CNR1CNR2CA2LPLLIPG | |
| SCHEMBL16962245 | 0.85 | CTSS (0.35) | CNR1CNR2 | |
| SCHEMBL298886 | 0.84 | HPGD (0.45) | CA2GPR84CYP3A4PTGS2 | |
| SCHEMBL17046404 | 0.84 | CNR1 (0.32) | CNR1CNR2CA2 | |
| SCHEMBL292013 | 0.84 | NPC1 (0.36) | CNR1CNR2CA2GPR84 | |
| SCHEMBL16958877 | 0.84 | CNR1 (0.32) | CNR1CNR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| WO-2024037146-A1 | ELECTROLYTE SOLUTION AND BATTERY | 珠海冠宇电池股份有限公司 | 2024-02-22 | — | — | WO | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3550657-B1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO LTD (CN) | 2023-06-28 | — | — | EP | claimed |
| CN-115312855-A | Electrolyte and battery | 珠海冠宇电池股份有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-115043885-A | Chiral tridentate phosphine ligand as well as preparation method and application thereof | 南方科技大学 | 2022-09-13 | — | — | CN | claimed |
| CN-114335718-A | Non-aqueous electrolyte, preparation method thereof and secondary battery | 惠州市豪鹏科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-107293781-B | Electrolyte and lithium ion battery | 宁德新能源科技有限公司 | 2020-06-12 | — | — | CN | claimed |
| US-20190267671-A1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2019-08-29 | — | — | US | claimed |
| WO-2010101993-A2 | TRIANIONIC PINCER LIGANDS, A CR(III)/CR(V) CATALYTIC SYSTEM AND ITS USE FOR CATALYTIC AEROBIC OXIDATION OF ORGANIC SUBSTRATES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-7161018-B2 | Soluble late transition metal catalysts for olefin oligomerizations II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-01-09 | — | — | US | claimed |
| EP-1513854-B1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS | EXXONMOBIL CHEM PATENTS INC (US) | 2006-11-29 | — | — | EP | claimed |
| US-5767277-A | REDUCING AGENT FOR A CARBONYL COMPOUND TO PRODUCE A 1,3-SYN-DIOL COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| US-5663348-A | REDUCTION OF DIKETONE WITH AMINOALKOXYBORANE COMPLEX TO FORM DIALCOHOL ESTER COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1997-09-02 | — | — | US | claimed |
| CN-114300745-B | Non-aqueous electrolyte, secondary battery and application of thiophosphamide as electrolyte additive | 惠州市豪鹏科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | disclosed |
| CN-118040054-A | Electrolyte and battery | 珠海冠宇电池股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-0680484-A1 | OPTICALLY ACTIVE $g(b)-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017079-A1 | OPTICALLY ACTIVE β-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-08-04 | — | — | WO | disclosed |
| US-4035403-A | BACTERICIDES | CINCINNATI MILACRON, INC. (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | CNR1 572/4885CNR2 1058/4885CA2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.